Difference between revisions of "NIH royalties"
Jump to navigation
Jump to search
(The vaccine mandates at school for HPV boosted NIH revenues) |
m |
||
| Line 4: | Line 4: | ||
The vaccine mandates at school for [[HPV]] boosted NIH revenues: | The vaccine mandates at school for [[HPV]] boosted NIH revenues: | ||
| − | {{cquote|And the three best-selling products utilizing technology licensed from NIH [in 2014] were Janssen’s Prezista, a novel protease inhibitor for the treatment of HIV-1 in patients who are non-responsive to existing antiretroviral therapies, Merck’s Gardasil, a vaccine to protect against cervical cancer, and AstraZeneca’s Synagis, a monoclonal antibody for the treatment of Respiratory Syncytial Virus (RSV) in infants.<ref>https://www.raps.org/news-and-articles/news-articles/2019/4/how-biopharma-companies-use-nih-and-vice-versa</ref>}} | + | {{cquote|And the three best-selling products utilizing technology licensed from NIH [in 2014] were Janssen’s Prezista, a novel protease inhibitor for the treatment of HIV-1 in patients who are non-responsive to existing antiretroviral therapies, Merck’s [[Gardasil]], a vaccine to protect against cervical cancer, and AstraZeneca’s Synagis, a monoclonal antibody for the treatment of Respiratory Syncytial Virus (RSV) in infants.<ref>https://www.raps.org/news-and-articles/news-articles/2019/4/how-biopharma-companies-use-nih-and-vice-versa</ref>}} |
== References == | == References == | ||
{{reflist}} | {{reflist}} | ||
{{coronavirus}} | {{coronavirus}} | ||
[[category:patent law]] | [[category:patent law]] | ||
Revision as of 01:02, April 11, 2022
NIH royalties on its patents can enrich the bureaucracy and its officers.
Since 2017, the royalty income has been declining, which have increased the pressure at the NIH to push for patentable vaccines rather than inexpensive medications for treating COVID-19.[1]
The vaccine mandates at school for HPV boosted NIH revenues:
| “ | And the three best-selling products utilizing technology licensed from NIH [in 2014] were Janssen’s Prezista, a novel protease inhibitor for the treatment of HIV-1 in patients who are non-responsive to existing antiretroviral therapies, Merck’s Gardasil, a vaccine to protect against cervical cancer, and AstraZeneca’s Synagis, a monoclonal antibody for the treatment of Respiratory Syncytial Virus (RSV) in infants.[2] | ” |